Leung R, Hill P, Burdon J
Department of Respiratory Medicine, St Vincent's Hospital, Victoria, Australia.
Thorax. 1996 Jun;51(6):596-600. doi: 10.1136/thx.51.6.596.
Inhaled morphine has previously been shown to increase exercise endurance in patients with chronic lung disease. A similar study was performed to determine whether inhaled morphine reduces the sensation of breathlessness in this group of patients.
A randomised double blind study on the effect of nebulised morphine on both exercise induced breathlessness and maximum achievable power output using isotonic saline as a control was performed in 10 patients with stable chronic lung disease. Each subject performed a progressive exercise test (Jones' stage I) on an electrically braked cycle ergometer. The work load was increased by 10 watts per minute and subjects exercised to exhaustion. At the end of each minute of exercise patients were asked to rate their degree of breathlessness according to a modified Borg scale. All subjects were randomised to receive either inhaled morphine sulphate 1 mg/ml (5 ml) or isotonic saline (5 ml) by wet nebulisation. The effect of morphine and saline on the achieved exercise capacity and the development of breathlessness during exercise was tested on separate days.
The mean dose of morphine inhaled was 1.24 mg. There was no difference in maximum power output achieved, minute ventilation at maximum power output, nor the degree of breathlessness at maximum power output between the groups treated with morphine and placebo. The degree of breathlessness was related to the power output achieved during exercise by a power function relationship (mean r: morphine = 0.86, saline = 0.87). However, there was a wide variation in the sensation for any given power output in both groups. There was no difference in the group mean slopes (morphine = 1.15, saline = 1.00) or intercepts (morphine = 0.07, saline = 0.15) in this relationship between the morphine and saline treatment groups.
In patients with severe chronic lung disease inhaled morphine in the doses used in this study does not relieve exercise induced breathlessness nor does it increase maximum power output achieved during progressive exercise.
此前已有研究表明,吸入吗啡可提高慢性肺病患者的运动耐力。本研究旨在确定吸入吗啡是否能减轻该组患者的呼吸急促感。
对10例稳定期慢性肺病患者进行了一项随机双盲研究,以雾化吗啡对运动诱发的呼吸急促和使用等渗盐水作为对照的最大可实现功率输出的影响。每位受试者在电动制动的自行车测力计上进行渐进性运动试验(琼斯I期)。工作量每分钟增加10瓦,受试者运动至疲惫。在运动的每分钟末,要求患者根据改良的博格量表对其呼吸急促程度进行评分。所有受试者随机接受雾化吸入1mg/ml硫酸吗啡(5ml)或等渗盐水(5ml)。分别在不同日期测试吗啡和盐水对运动能力和运动过程中呼吸急促发展的影响。
吸入吗啡的平均剂量为1.24mg。在接受吗啡治疗和安慰剂治疗的组之间,最大输出功率、最大功率输出时的分钟通气量以及最大功率输出时的呼吸急促程度均无差异。呼吸急促程度与运动过程中通过幂函数关系实现的功率输出相关(平均r:吗啡=0.86,盐水=0.87)。然而,两组中任何给定功率输出的感觉存在很大差异。吗啡和盐水治疗组之间在这种关系中的组平均斜率(吗啡=1.15,盐水=1.00)或截距(吗啡=0.07,盐水=0.15)没有差异。
在本研究使用的剂量下,吸入吗啡并不能缓解重度慢性肺病患者运动诱发的呼吸急促,也不会增加渐进性运动过程中实现的最大输出功率。